aztreonam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
monobactam antibiotics 279 78110-38-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cayston
  • aztreonam
  • azonam
  • azthreonam
  • aztreon
  • monobactam
  • nebactam
  • primbactam
  • aztreonam lysine
  • azactam
A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
  • Molecular weight: 435.43
  • Formula: C13H17N5O8S2
  • CLOGP: -0.36
  • LIPINSKI: 1
  • HAC: 13
  • HDO: 4
  • TPSA: 201.58
  • ALOGS: -3.34
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.23 g Inhal.solution
4 g P
6 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 68 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 305.44 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 1 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.18 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.40 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.50 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -2.723 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.525 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.058 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 2.559 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 39.840 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 52.820 % High 1
herg hERG pIC50 4.435 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 2.972 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 4.416 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 41.280 % High 1
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,ITK,JAK1,JAK2,JAK3,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MTOR,NTRK1,NTRK2,PDK1,PDK2,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK 52
kinase-selectivity-class AXL,CDK9,EPHB4,GRK2,MAP2K6,MAP3K14,MAPK7,PRKDC,STK33,SYK,TEK 11
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.284 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.223 High 1
mh-clint Mouse hepatocyte intrinsic clearance 13.996 High 1
mppb Mouse plasma protein binding (% unbound) 57.540 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.101 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 46.440 % High 1
rat-kpuu-brain Rat brain Kpuu 0.005 % High 1
rh-clint Rat hepatocyte intrinsic clearance 4.977 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 87.670 % High 1
rppb Rat plasma protein binding (% unbound) 31.620 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 868.960 uM High 1

Approvals:

DateAgencyCompanyOrphan
Dec. 31, 1986 FDA BRISTOL MYERS SQUIBB
Sept. 21, 2009 EMA GILEAD SCIENCES IRELAND UC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis 1811.77 25.28 375 9542 9904 90608626
Cystic fibrosis 440.11 25.28 99 9818 3842 90614688
Death 324.21 25.28 318 9599 456233 90162297
Bacterial disease carrier 310.02 25.28 65 9852 1801 90616729
Bronchial secretion retention 272.34 25.28 66 9851 3549 90614981
Lung transplant 265.86 25.28 65 9852 3627 90614903
Superinfection 256.00 25.28 61 9856 3051 90615479
Pulmonary function test decreased 228.92 25.28 60 9857 4434 90614096
Haemoptysis 225.35 25.28 97 9820 33223 90585307
Eosinophilia 219.39 25.28 91 9826 28442 90590088
Bronchospasm 186.49 25.28 74 9843 20635 90597895
Hospitalisation 180.99 25.28 133 9784 127967 90490563
Scoliosis 180.13 25.28 58 9859 8849 90609681
Pseudomonas infection 154.67 25.28 59 9858 14806 90603724
Sinus operation 152.64 25.28 40 9877 2951 90615579
Cystic fibrosis respiratory infection suppression 149.76 25.28 27 9890 328 90618202
Atelectasis 145.34 25.28 65 9852 24344 90594186
Aggression 133.65 25.28 63 9854 26605 90591925
Rib fracture 124.99 25.28 60 9857 26375 90592155
Respiratory failure 123.89 25.28 103 9814 118315 90500215
Nonspecific reaction 121.68 25.28 33 9884 2776 90615754
Treatment noncompliance 116.99 25.28 72 9845 51655 90566875
Off label use 99.37 25.28 304 9613 1101948 89516582
Sleep disorder due to a general medical condition 97.93 25.28 61 9856 44677 90573853
Cough 91.85 25.28 153 9764 368809 90249721
Illness 87.14 25.28 72 9845 81897 90536633
Drug reaction with eosinophilia and systemic symptoms 80.44 25.28 53 9864 42705 90575825
Heart rate increased 65.68 25.28 71 9846 112831 90505699
Sinus disorder 65.52 25.28 43 9874 34404 90584126
Sputum increased 62.83 25.28 20 9897 2937 90615593
Atrial fibrillation 60.80 25.28 74 9843 133537 90484993
Anxiety 53.68 25.28 110 9807 309662 90308868
Bronchiectasis 52.80 25.28 32 9885 22298 90596232
Distal intestinal obstruction syndrome 52.21 25.28 12 9905 511 90618019
Agranulocytosis 50.80 25.28 37 9880 34965 90583565
Forced expiratory volume decreased 49.64 25.28 20 9897 5788 90612742
Myalgia 49.43 25.28 77 9840 175048 90443482
Impaired quality of life 49.22 25.28 31 9886 23113 90595417
Transplant 48.61 25.28 13 9904 1036 90617494
Pancreatic failure 48.49 25.28 14 9903 1478 90617052
Dyspnoea 45.16 25.28 203 9714 880752 89737778
Pulmonary haemorrhage 43.44 25.28 20 9897 7993 90610537
Pneumonia 42.08 25.28 159 9758 637900 89980630
Wheezing 41.75 25.28 85 9832 237995 90380535
Palpitations 41.22 25.28 62 9855 136666 90481864
Therapeutic product effect incomplete 41.07 25.28 75 9842 193821 90424709
Drug resistance 39.30 25.28 30 9887 30419 90588111
Lung disorder 38.30 25.28 63 9854 149820 90468710
Infection 38.16 25.28 106 9811 361988 90256542
Productive cough 37.19 25.28 44 9873 77019 90541511
Mucormycosis 35.58 25.28 14 9903 3807 90614723
Loss of personal independence in daily activities 34.49 25.28 57 9860 136048 90482482
Pathogen resistance 34.09 25.28 17 9900 8098 90610432
Blood pressure increased 32.89 25.28 69 9848 197148 90421382
Cholestatic liver injury 32.19 25.28 13 9904 3784 90614746
Infusion related reaction 31.96 25.28 4 9913 416776 90201754
Joint swelling 31.75 25.28 8 9909 503292 90115238
Chest discomfort 29.88 25.28 54 9863 138311 90480219
Asthma 29.65 25.28 75 9842 242085 90376445
Disseminated mucormycosis 29.60 25.28 8 9909 663 90617867
Arthropathy 29.37 25.28 3 9914 366239 90252291
Toxic skin eruption 28.31 25.28 19 9898 15755 90602775
Toxic epidermal necrolysis 25.38 25.28 24 9893 32504 90586026

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis 928.92 23.62 216 5796 7602 42607721
Cystic fibrosis 364.82 23.62 79 5933 1976 42613347
Lung transplant 336.71 23.62 76 5936 2310 42613013
Death 179.90 23.62 271 5741 470914 42144409
Hospitalisation 138.96 23.62 101 5911 74229 42541094
Eosinophilia 114.17 23.62 66 5946 32833 42582490
Pulmonary function test decreased 90.29 23.62 33 5979 5699 42609624
Cystic fibrosis respiratory infection suppression 86.47 23.62 17 5995 258 42615065
Pseudomonas infection 83.38 23.62 42 5970 15881 42599442
Rash maculo-papular 72.31 23.62 52 5960 37451 42577872
Haemoptysis 71.21 23.62 56 5956 46111 42569212
Respiratory failure 63.49 23.62 84 5928 128048 42487275
Off label use 60.85 23.62 212 5800 638123 41977200
Hepatic cytolysis 58.19 23.62 40 5972 26804 42588519
Sputum increased 52.75 23.62 19 5993 3144 42612179
Drug reaction with eosinophilia and systemic symptoms 52.22 23.62 45 5967 42030 42573293
Infection 50.21 23.62 70 5942 111998 42503325
Cystic fibrosis related diabetes 48.84 23.62 10 6002 188 42615135
Pathogen resistance 47.91 23.62 26 5986 11424 42603899
Leukocytosis 47.87 23.62 37 5975 29671 42585652
Toxic epidermal necrolysis 46.81 23.62 35 5977 26715 42588608
Productive cough 42.58 23.62 44 5968 51523 42563800
Infective exacerbation of bronchiectasis 39.64 23.62 10 6002 489 42614834
Septic shock 36.26 23.62 54 5958 91618 42523705
Lung disorder 36.20 23.62 39 5973 47884 42567439
Rash morbilliform 34.25 23.62 15 5997 4138 42611185
Distal intestinal obstruction syndrome 29.82 23.62 8 6004 499 42614824
Condition aggravated 29.38 23.62 92 5920 260662 42354661
Tracheostomy 28.23 23.62 9 6003 1028 42614295
Cough 28.06 23.62 71 5941 178032 42437291
Adrenergic syndrome 27.71 23.62 6 6006 149 42615174
Antibiotic level above therapeutic 26.45 23.62 7 6005 414 42614909
Pneumonia pseudomonal 25.83 23.62 13 5999 4896 42610427
Sputum discoloured 24.10 23.62 16 5996 10116 42605207
Pancreatic failure 23.80 23.62 8 6004 1079 42614244
Influenza 23.67 23.62 36 5976 62139 42553184

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis 2107.28 21.37 460 12798 14311 110561730
Cystic fibrosis 594.07 21.37 133 13125 4598 110571443
Lung transplant 437.73 21.37 106 13152 5180 110570861
Eosinophilia 340.35 21.37 157 13101 57779 110518262
Bacterial disease carrier 280.46 21.37 63 13195 2206 110573835
Death 271.00 21.37 373 12885 698496 109877545
Bronchial secretion retention 249.45 21.37 67 13191 4957 110571084
Pulmonary function test decreased 246.90 21.37 75 13183 8625 110567416
Haemoptysis 216.62 21.37 124 13134 71230 110504811
Superinfection 213.15 21.37 61 13197 5702 110570339
Hospitalisation 189.29 21.37 148 13110 142345 110433696
Scoliosis 172.00 21.37 57 13201 8676 110567365
Cystic fibrosis respiratory infection suppression 163.48 21.37 31 13227 458 110575583
Pseudomonas infection 161.92 21.37 75 13183 27778 110548263
Bronchospasm 159.08 21.37 76 13182 30163 110545878
Sinus operation 149.00 21.37 40 13218 2951 110573090
Drug reaction with eosinophilia and systemic symptoms 135.07 21.37 97 13161 81998 110494043
Atelectasis 117.26 21.37 66 13192 36646 110539395
Nonspecific reaction 115.74 21.37 33 13225 3041 110573000
Respiratory failure 101.54 21.37 127 13131 215205 110360836
Rib fracture 100.56 21.37 58 13200 33712 110542329
Sputum increased 99.27 21.37 34 13224 5717 110570324
Treatment noncompliance 95.05 21.37 75 13183 72915 110503126
Off label use 90.28 21.37 386 12872 1499799 109076242
Sleep disorder due to a general medical condition 84.36 21.37 61 13197 52051 110523990
Aggression 83.96 21.37 64 13194 59146 110516895
Rash maculo-papular 77.29 21.37 67 13191 74155 110501886
Distal intestinal obstruction syndrome 76.92 21.37 19 13239 1006 110575035
Toxic epidermal necrolysis 75.37 21.37 59 13199 56668 110519373
Pathogen resistance 70.99 21.37 37 13221 17635 110558406
Cough 67.77 21.37 162 13096 461479 110114562
Pancreatic failure 65.51 21.37 20 13238 2334 110573707
Infective exacerbation of bronchiectasis 64.53 21.37 16 13242 860 110575181
Forced expiratory volume decreased 62.89 21.37 31 13227 13145 110562896
Sinus disorder 61.55 21.37 42 13216 32686 110543355
Illness 60.17 21.37 61 13197 82110 110493931
Hepatic cytolysis 51.93 21.37 47 13211 55006 110521035
Septic shock 51.65 21.37 78 13180 157450 110418591
Drug resistance 50.97 21.37 47 13211 56327 110519714
Heart rate increased 49.70 21.37 73 13185 143761 110432280
Pneumonia 48.12 21.37 220 13038 876494 109699547
Productive cough 46.90 21.37 63 13195 114242 110461799
Acute generalised exanthematous pustulosis 46.03 21.37 30 13228 21634 110554407
Agranulocytosis 45.48 21.37 46 13212 61714 110514327
Transplant 44.93 21.37 13 13245 1261 110574780
Impaired quality of life 43.76 21.37 33 13225 29984 110546057
Cystic fibrosis related diabetes 43.24 21.37 9 13249 218 110575823
Pneumonia pseudomonal 42.84 21.37 20 13238 7526 110568515
Bronchiectasis 42.19 21.37 35 13223 36458 110539583
Leukocytosis 41.31 21.37 41 13217 53787 110522254
Wheezing 41.13 21.37 93 13165 255137 110320904
Dyspnoea 40.93 21.37 249 13009 1106623 109469418
Toxic skin eruption 35.21 21.37 28 13230 27487 110548554
Fatigue 34.61 21.37 58 13200 1215900 109360141
Tracheostomy 34.24 21.37 11 13247 1516 110574525
Anxiety 33.39 21.37 104 13154 344974 110231067
Rash morbilliform 32.94 21.37 17 13241 7934 110568107
Lung disorder 32.86 21.37 69 13189 179978 110396063
Asthma 32.59 21.37 84 13174 250207 110325834
Joint swelling 31.99 21.37 7 13251 442838 110133203
Palpitations 31.39 21.37 63 13195 159149 110416892
Myalgia 30.37 21.37 76 13182 222305 110353736
Toxicity to various agents 30.19 21.37 10 13248 480545 110095496
Blood alkaline phosphatase increased 28.94 21.37 39 13219 70896 110505145
Disease complication 28.67 21.37 14 13244 5813 110570228
Peripheral swelling 27.96 21.37 7 13251 404027 110172014
Atrial fibrillation 27.78 21.37 75 13183 229567 110346474
Chest discomfort 27.60 21.37 63 13195 173785 110402256
Pneumothorax 27.30 21.37 27 13231 35258 110540783
Sputum discoloured 26.62 21.37 24 13234 27921 110548120
Pain in extremity 25.95 21.37 13 13245 487105 110088936
Diarrhoea 25.84 21.37 62 13196 1139443 109436598
Shock 25.83 21.37 32 13226 53556 110522485
Rheumatoid arthritis 25.51 21.37 3 13255 299610 110276431
Adrenergic syndrome 25.22 21.37 6 13252 271 110575770
Hypoaesthesia 24.74 21.37 4 13254 314219 110261822
Loss of personal independence in daily activities 24.52 21.37 55 13203 149965 110426076
Muscle spasms 23.16 21.37 3 13255 278154 110297887
Therapeutic product effect incomplete 23.07 21.37 69 13189 223736 110352305
Cholestatic liver injury 22.83 21.37 13 13245 7363 110568678
Confusional state 22.80 21.37 14 13244 468666 110107375
Multiple-drug resistance 22.57 21.37 16 13242 13219 110562822
Hypertension 22.46 21.37 17 13241 510067 110065974
Pseudomonas test positive 22.45 21.37 9 13249 2345 110573696
Infusion related reaction 22.12 21.37 9 13249 381153 110194888
Pulmonary haemorrhage 21.60 21.37 17 13241 16439 110559602
Antibiotic level above therapeutic 21.37 21.37 7 13251 1026 110575015

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pulmonary haemorrhage 25.33 20.04 6 7 370 113570

Pharmacologic Action:

SourceCodeDescription
ATC J01DF01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Monobactams
ATC J01DF51 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Monobactams
FDA CS M0014030 Monobactams
FDA EPC N0000175493 Monobactam Antibacterial
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:50696 EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
CHEBI has role CHEBI:88188 drug allergen

Related Drugs by ATC class:

J01DF Monobactams 1 drug
carumonam

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Septicemia due to Escherichia coli indication 9323009
Infection due to Pseudomonas aeruginosa indication 11218009
Infection of skin AND/OR subcutaneous tissue indication 19824006
Pneumonia due to Pseudomonas indication 41381004
Peritonitis indication 48661000
Lower respiratory tract infection indication 50417007
Pneumonia due to Escherichia coli indication 51530003
Klebsiella cystitis indication 60867007
Urinary tract infectious disease indication 68566005
Haemophilus influenzae pneumonia indication 70036007
Infection due to Escherichia coli indication 71057007
Bacterial infection due to Serratia indication 71120004
Rhinoscleroma indication 72409005 DOID:11336
Endometritis indication 78623009 DOID:1002
Septicemia due to Serratia indication 82091000
Female genital tract infection indication 125585007
Infectious disease of abdomen indication 128070006
Infection due to Enterobacteriaceae indication 128945009
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Proteus pneumonia indication 195888009
Bacterial peritonitis indication 197171003
Proteus septicemia indication 300986008
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Bacterial urinary infection indication 312124009
Sepsis due to Pseudomonas indication 448813005
Sepsis due to Gram negative bacteria indication 449082003
Gram-Negative Aerobic Bacillary Pneumonia indication
Serratia Urinary Tract Infection indication
E. Coli Pelvic Inflammatory Disease indication
Enterobacter Pneumonia indication
Citrobacter Urinary Tract Infection indication
Skin and Skin Structure Proteus Infection indication
Skin and Skin Structure Pseudomonas Aeruginosa Infection indication
Haemophilus Influenzae Bronchitis indication
E. Coli Bronchitis indication
Respiratory Cystic Fibrosis with Pseudomonas aeruginosa Colonization indication
Skin and Skin Structure Serratia Infection indication
Inflammatory Disease of Female Pelvic Organs indication
Proteus Pelvic Inflammatory Disease indication
E. Coli Endometritis indication
Enterobacter Cloacae Bronchitis indication
Serratia Bronchitis indication
Pseudomonas Aeruginosa Bronchitis indication
Citrobacter Peritonitis indication
Aerobic Gram-Negative Bacteremia indication
E. Coli Peritonitis indication
Enterobacter Endometritis indication
Skin and Skin Structure Citrobacter Infection indication
Serratia Peritonitis indication
Enterobacter Pelvic Inflammatory Disease indication
Klebsiella Endometritis indication
Pseudomonas Aeruginosa Urinary Tract Infection indication
Klebsiella Pelvic Inflammatory Disease indication
Bacterial Exacerbation of Acute Bronchitis indication
Proteus Bronchitis indication
Proteus Endometritis indication
Klebsiella Pneumoniae Peritonitis indication
Bronchospasm contraindication 4386001
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.44 acidic
pKa2 2.83 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.5GM BASE/VIAL;1.5GM/VIAL EMBLAVEO ABBVIE N217906 Feb. 7, 2025 RX POWDER INTRAVENOUS 7112592 Jan. 7, 2026 TREATMENT OF COMPLICATED INTRA-ABDOMINAL BACTERIAL INFECTIONS IN ADULT PATIENTS

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 0.5GM BASE/VIAL;1.5GM/VIAL EMBLAVEO ABBVIE N217906 Feb. 7, 2025 RX POWDER INTRAVENOUS Feb. 7, 2028 NEW PRODUCT
EQ 0.5GM BASE/VIAL;1.5GM/VIAL EMBLAVEO ABBVIE N217906 Feb. 7, 2025 RX POWDER INTRAVENOUS Feb. 7, 2033 GENERATING ANTIBIOTIC INCENTIVES NOW

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Penicillin-binding protein 1A Enzyme INHIBITOR IC50 5.32 WOMBAT-PK CHEMBL
Penicillin-binding protein 1B Enzyme INHIBITOR IC50 4.32 WOMBAT-PK CHEMBL
Peptidoglycan synthase FtsI Enzyme INHIBITOR IC50 5.74 WOMBAT-PK CHEMBL
Beta-lactamase Enzyme IC50 7.49 CHEMBL
AmpC Enzyme IC50 7.22 CHEMBL
Efflux transporter; SugE Transporter IC50 8.22 CHEMBL
Beta-lactamase Enzyme IC50 8.22 CHEMBL
Beta-lactamase Enzyme Ki 8.15 CHEMBL
Beta-lactamase Enzyme Ki 5.52 CHEMBL
Penicillin-binding protein 1A Enzyme IC50 5.48 CHEMBL
Beta-lactamase Enzyme Ki 5.70 CHEMBL

External reference:

IDSource
D00240 KEGG_DRUG
827611-49-4 SECONDARY_CAS_RN
1272 RXNORM
C0004521 UMLSCUI
CHEBI:161680 CHEBI
T6O PDB_CHEM_ID
CHEMBL158 ChEMBL_ID
CHEMBL3833340 ChEMBL_ID
D001398 MESH_DESCRIPTOR_UI
DB00355 DRUGBANK_ID
10763 IUPHAR_LIGAND_ID
5159 INN_ID
G2B4VE5GH8 UNII
5742832 PUBCHEM_CID
167898 MMSL
170132 MMSL
2813 MMSL
4239 MMSL
d00067 MMSL
4017762 VANDF
4037186 VANDF
002807 NDDF
013342 NDDF
373297006 SNOMEDCT_US
387386004 SNOMEDCT_US
409132008 SNOMEDCT_US
409133003 SNOMEDCT_US
69918003 SNOMEDCT_US
734461007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
AZACTAM HUMAN PRESCRIPTION DRUG LABEL 1 0003-2560 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR NDA 21 sections
AZACTAM HUMAN PRESCRIPTION DRUG LABEL 1 0003-2570 INJECTION, POWDER, FOR SOLUTION 2 g INTRAMUSCULAR NDA 21 sections
EMBLAVEO HUMAN PRESCRIPTION DRUG LABEL 2 0074-3878 POWDER, FOR SOLUTION 127 mg INTRAVENOUS NDA 28 sections
Aztreonam HUMAN PRESCRIPTION DRUG LABEL 1 0409-0829 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAVENOUS ANDA 23 sections
Aztreonam HUMAN PRESCRIPTION DRUG LABEL 1 0409-0830 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS ANDA 23 sections
AZACTAM HUMAN PRESCRIPTION DRUG LABEL 1 50090-7494 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR NDA 20 sections
Aztreonam HUMAN PRESCRIPTION DRUG LABEL 1 63323-401 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAVENOUS ANDA 23 sections
Aztreonam HUMAN PRESCRIPTION DRUG LABEL 1 63323-401 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAVENOUS ANDA 23 sections
Aztreonam HUMAN PRESCRIPTION DRUG LABEL 1 63323-401 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRAVENOUS ANDA 23 sections
Aztreonam HUMAN PRESCRIPTION DRUG LABEL 1 63323-402 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 23 sections
Aztreonam HUMAN PRESCRIPTION DRUG LABEL 1 63323-402 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 23 sections
Aztreonam HUMAN PRESCRIPTION DRUG LABEL 1 63323-402 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 23 sections